CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report fourth quarter 2019 financial results on Thursday, February 27, 2020, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:00 p.m. ET to discuss its results.

Participants may access the live audio webcast of the teleconference from the “Investors & News” section of CytomX’s website at http://ir.cytomx.com/. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Audio Conference Call:

	U.S. Dial-in Number:	[phone]
	International Dial-in Number:	[phone]
	Conference ID:	1686972

An archived webcast replay will be available on the Company's website from February 27, 2020, until March 5, 2020.

About CytomX Therapeutics

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential best-in-class immunotherapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult to drug targets. Five novel drug-candidates utilizing our Probody technology are in clinical trials, with three in Phase 2 studies and two in Phase 1. These clinical programs include cancer immunotherapies against validated targets such as a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The CytomX clinical stage pipeline also includes first-in-class Probody drug conjugates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen and BMS. For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter.

PROBODY is a registered trademark of CytomX Therapeutics. Contact:

Investors and Media:

Christopher Keenan VP, Investor Relations and Corporate Communications [e-mail] 650-383-0823